Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) is now available.
Lepu Biopharma Co., Ltd. announced the presentation of pivotal clinical trial results for its drug candidate MRG003 at the 2025 ASCO Annual Meeting. MRG003, an innovative ADC targeting epidermal growth factor receptor, showed significant improvements in objective response rate and progression-free survival compared to chemotherapy in patients with recurrent or metastatic nasopharyngeal cancer. The study suggests a potential paradigm shift in treatment, demonstrating meaningful benefits while maintaining a manageable safety profile.
More about Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biopharmaceutical industry. The company focuses on developing innovative antibody drug conjugates (ADCs) targeting various cancer types, with a market focus on treatments for recurrent or metastatic cancers.
Average Trading Volume: 18,595,893
Technical Sentiment Signal: Buy
Current Market Cap: HK$7.94B
For detailed information about 2157 stock, go to TipRanks’ Stock Analysis page.